Current Mounjaro Supply Status
Update (March 2026): The FDA has resolved the tirzepatide shortage. Mounjaro and Zepbound are widely available at most pharmacies. The information below is retained for reference but the acute supply issues described are no longer current.
As of 2026, Mounjaro supply has returned to normal. Eli Lilly's manufacturing expansion has caught up with demand, and all dose strengths (2.5 mg through 15 mg) are available at most retail and mail-order pharmacies.
The acute shortages of 2024 are over. If you still have trouble filling a prescription, contact your pharmacy or provider — isolated supply blips can occur with any medication but are no longer the systemic issue they were.
Key distinction: Mounjaro is FDA-approved for type 2 diabetes only, not weight loss. Mounjaro (diabetes) and Zepbound (weight management) contain the same tirzepatide but are manufactured and distributed separately, so supply status may differ between products.
Why Tirzepatide Shortages Happened
- Unprecedented demand: Tirzepatide’s clinical results drove massive prescribing beyond manufacturing projections
- Complex manufacturing: Tirzepatide is a complex peptide requiring specialized production
- Multiple dose strengths: Six different doses require separate production runs
- Global demand: International competition for limited supply
Which Doses Were Affected
| Dose | 2026 Resolution Status |
|---|---|
| 2.5 mg | Available in most pharmacies |
| 5 mg | Available in most pharmacies |
| 7.5 mg | Largely resolved with occasional local delays |
| 10 mg | Largely resolved with occasional local delays |
| 12.5 mg | Available in most pharmacies |
| 15 mg | Resolved nationally with occasional local delays |
What Patients Did During Shortages
- Check multiple pharmacies and specialty pharmacies
- Consider mail-order pharmacy services
- Don’t stockpile—it worsens shortages for others
- Plan ahead—refill 5–7 days before your dose is due
- Stay in communication with your provider for alternatives
FDA-Approved Alternatives
- Wegovy (semaglutide 2.4 mg): GLP-1 agonist for weight management with strong efficacy
- Ozempic (semaglutide): For diabetes patients if Mounjaro is unavailable
- Trulicity (dulaglutide): Weekly GLP-1 injection for diabetes
PEAK maintains relationships with multiple pharmacy partners and monitors supply closely. When shortages affect one medication, we help patients transition smoothly to available alternatives.
About Compounded Tirzepatide
PEAK does not prescribe compounded tirzepatide. As with compounded semaglutide, these products are not FDA-approved and don’t undergo the same quality controls. The FDA has issued warnings about adverse events with compounded GLP-1 products.
Learn more: Why PEAK Doesn’t Prescribe Compounded GLP-1s
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
